[1]曾小兰.阿莫西林-克拉维酸钾、左氧氟沙星治疗下呼吸道感染的疗效及成本-效果分析[J].医学信息,2022,35(18):77-79.[doi:10.3969/j.issn.1006-1959.2022.18.019]
　ZENG Xiao-lan.Efficacy and Cost-effectiveness Analysis of Amoxicillin-clavulanate Potassium and Levofloxacin in Treatment of Lower Respiratory Tract Infection[J].Journal of Medical Information,2022,35(18):77-79.[doi:10.3969/j.issn.1006-1959.2022.18.019]
点击复制

阿莫西林-克拉维酸钾、左氧氟沙星治疗下呼吸道感染的疗效及成本-效果分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年18期
页码:
77-79
栏目:
论著
出版日期:
2022-09-15

文章信息/Info

Title:
Efficacy and Cost-effectiveness Analysis of Amoxicillin-clavulanate Potassium and Levofloxacin in Treatment of Lower Respiratory Tract Infection
文章编号:
1006-1959（2022）18-0077-03
作者:
曾小兰
（永丰县人民医院感染科，江西 永丰 331500）
Author(s):
ZENG Xiao-lan
(Department of Infection,Yongfeng County People’s Hospital,Yongfeng 331500,Jiangxi,China)
关键词:
阿莫西林克拉维酸钾; 左氧氟沙星; 下呼吸道感染; 成本-效果
Keywords:
Amoxicillin clavulanate potassium; Levofloxacin; Lower respiratory tract infection; Cost-effectiveness
分类号:
R56
DOI:
10.3969/j.issn.1006-1959.2022.18.019
文献标志码:
A
摘要:
目的 研究阿莫西林-克拉维酸钾、左氧氟沙星治疗下呼吸道感染的疗效及成本-效果。方法 选择2016年2月-2018年2月在我院诊治的60例下呼吸道感染患者为研究对象，依照随机数字表法将研究对象分为对照组和观察组，各30例。对照组患者给予左氧氟沙星治疗，观察组采用阿莫西林-克拉维酸钾治疗，比较两组临床治疗总有效率、成本-效果、炎性因子水平以及临床不良反应发生情况。结果 观察组治疗率总有效率为93.33%，高于对照组的73.33%（P＜0.05）；两组成本-效果比较，差异无统计学意义（P＞0.05）；两组治疗后WBC、N、CRP均低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率为33.33%，与对照组的36.67%比较，差异无统计学意义（P＞0.05）。结论 阿莫西林-克拉维酸钾治疗下呼吸道感染效果优于左氧氟沙星，可提高治疗总有效率，降低炎性因子水平，且未增加不良反应，有助于提升成本-效果。
Abstract:
Objective To study the efficacy and cost-effectiveness of amoxicillin clavulanate potassium and levofloxacin in the treatment of lower respiratory tract infection.Methods Sixty patients with lower respiratory tract infection diagnosed and treated in our hospital from February 2016 to February 2018 were selected as the research objects. They were divided into control group and observation group by random number table method, with 30 cases in each group. The control group was treated with levofloxacin, and the observation group was treated with amoxicillin-clavulanate potassium. The total effective rate, cost-effectiveness, inflammatory factor level and incidence of clinical adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 93.33%, which was higher than 73.33% of the control group(P<0.05). There was no significant difference in cost-effectiveness between the two groups (P>0.05). The WBC, N and CRP of the two groups after treatment were lower than those before treatment, and the observation group was lower than the control group, the (P<0.05). The incidence of adverse reactions in the observation group was 33.33%, which was compared with 36.67% in the control group(P>0.05).Conclusion Amoxicillin-clavulanate potassium is better than levofloxacin in the treatment of lower respiratory tract infection, which can improve the total effective rate, reduce the level of inflammatory factors, and will not increase the adverse reactions, improve the cost-effectiveness, and has significant application advantages.

参考文献/References:

[1]马德忠,马才惠.莫西沙星序贯疗法在老年下呼吸道感染中的应用及对血清炎性因子的影响[J].河北医药,2017,39(5):710-712.[2]孙常武,庄梅.下呼吸道感染采用不同抗生素方案治疗药学分析[J].中西医结合心血管病电子杂志,2018,6(12):182.[3]赵青,吴立强,周湘荃,等.喜炎平联合左氧氟沙星治疗COPD急性加重期下呼吸道细菌感染疗效观察[J].海南医学,2019,30(18):2412-2414.[4]Unger SA,Bogaert D.The respiratory microbiome and respiratory infections[J].J Infect,2017,74 Suppl 1:S84-S88.[5]刘春花,周志愉,孙法莹,等.左氧氟沙星联合润肺膏治疗慢性支气管炎的疗效分析[J].中国药房,2016,27(33):4649-4651.[6]Mahowald M,Shahan B,Forbes D.Respiratory conditions: lower respiratory tract infections[J].FP Essent,2019,486:19-25.[7]黄汉琮,杨晓蕊,曾林祥,等.阿奇霉素与左氧氟沙星治疗社区获得性下呼吸道感染疗效对比观察[J].中华医院感染学杂志,2016,26(16):3685-3687.[8]何薇,李明晖,苏美霞,等.银黄清肺胶囊联合左氧氟沙星治疗下呼吸道肺炎支原体感染的临床研究[J].中华中医药学刊,2016(6):1418-1420.[9]Zhang L,Hu P.Cost-effectiveness analysis of oral versus intravenous drip infusion of levofloxacin in the treatment of acute lower respiratory tract infection in Chinese elderly patients[J].Clin Interv Aging,2017,12:673-678.[10]肖文香,刘红梅,林忠贤.左氧氟沙星对老年AECOPD合并肺部感染患者免疫功能及预后的影响[J].海南医学,2020,31(2):30-33.[11]张特,罗小春,王斌,等.阿莫西林克拉维酸钾干混悬剂联合异丙托溴铵雾化吸入治疗支气管哮喘患者合并肺部感染的疗效[J].中华医院感染学杂志,2018(11):1654-1657.[12]Zhang L,Liu B,Wang C.Pharmaceutical analysis of different antibiotic regimens in the treatment of lower respiratory tract infection[J].Exp Ther Med,2018,16(3):2369-2374.[13]徐敏,胡岗,刘晓,等.头孢哌酮/舒巴坦联合莫西沙星治疗COPD合并急性下呼吸道感染临床疗效及对血清相关因子的影响[J].西部医学,2019,31(3):94-99.[14]周珊,刘家云,曲芬,等.喹诺酮类药物对2018—2020年多中心临床分离菌的耐药性分析[J].中国抗生素杂志,2021,46(11):1050-1053.[15]孙铁英.从指南看呼吸喹诺酮类药物在下呼吸道感染中的治疗地位[J].临床药物治疗杂志,2019,17(12):29-32,56.[16]刘春花,周志愉,孙法莹,等.左氧氟沙星联合润肺膏治疗慢性支气管炎的疗效分析[J].中国药房,2016,27(33):4649-4651.[17]李辛.左氧氟沙星三联疗法与注射用阿莫西林克拉维酸钾三联疗法治疗消化性溃疡的疗效[J].山西医药杂志,2018,47(5):579-580.[18]魏成翠,任艳.阿莫西林克拉维酸钾联合左氧氟沙星治疗耐多药肺结核的疗效及对血清腺苷脱氨酶、C反应蛋白水平的影响[J].中国医院用药评价与分析,2018(2):195-196,199.[19]任丽敏,马瑞,沈明,等.阿莫西林克拉维酸钾干混悬剂(7∶1)治疗儿童支气管哮喘合并肺部感染的效果观察[J].临床合理用药,2016,9(11):49-50.[20]陈平,谢宇.阿莫西林-克拉维酸钾对社区获得性肺炎患者的临床疗效及其对炎症因子水平的影响[J].抗感染药学,2018,15(11):1888-1890.

相似文献/References:

[1]李秀杰.含左氧氟沙星化疗方案治疗耐利福平结核病的预后分析[J].医学信息,2019,32(02):159.[doi:10.3969/j.issn.1006-1959.2019.02.048]
　LI Xiu-jie.Prognosis Analysis of Levofloxacin-containing Chemotherapy for Rifampicin-resistant Tuberculosis[J].Journal of Medical Information,2019,32(18):159.[doi:10.3969/j.issn.1006-1959.2019.02.048]
[2]冯瑞丰.阿奇霉素治疗急性细菌性下呼吸道感染的 有效性和安全性评价[J].医学信息,2019,32(11):152.[doi:10.3969/j.issn.1006-1959.2019.11.045]
　FENG Rui-feng.Evaluation of the Efficacy and Safety of Azithromycin in the Treatment of Acute Bacterial Lower Respiratory Tract Infections[J].Journal of Medical Information,2019,32(18):152.[doi:10.3969/j.issn.1006-1959.2019.11.045]
[3]隋文峰,潘 雪.左氧氟沙星联合头孢哌酮舒巴坦治疗老年肺炎的疗效及其对肺功能的影响[J].医学信息,2020,33(06):156.[doi:10.3969/j.issn.1006-1959.2020.06.052]
　SUI Wen-feng,PAN Xue.Effect of Levofloxacin Combined with Cefoperazone Sulbactam in the Treatment of Senile Pneumonia and Its Effect on Lung Function[J].Journal of Medical Information,2020,33(18):156.[doi:10.3969/j.issn.1006-1959.2020.06.052]
[4]蔡文斌.阿莫西林克拉维酸钾联合雾化吸入治疗小儿支气管肺炎的效果及对PCT、CRP的影响[J].医学信息,2022,35(19):68.[doi:10.3969/j.issn.1006-1959.2022.19.018]
　CAI Wen-bin.Effect of Amoxicillin and Clavulanate Potassium Combined with Aerosol Inhalation on Children with Bronchial Pneumonia and Its Influence on PCT and CRP[J].Journal of Medical Information,2022,35(18):68.[doi:10.3969/j.issn.1006-1959.2022.19.018]
[5]曾文宏,叶芳芳,周志明.哌拉西林钠他唑巴坦钠联合左氧氟沙星治疗慢性支气管炎的临床疗效及安全性观察[J].医学信息,2022,35(23):140.[doi:10.3969/j.issn.1006-1959.2022.23.029]
　ZENG Wen-hong,YE Fang-fang,ZHOU Zhi-ming.Observation on Clinical Efficacy and Safety of Piperacillin Sodium and Tazobactam Sodium Combined with Levofloxacin in the Treatment of Chronic Bronchitis[J].Journal of Medical Information,2022,35(18):140.[doi:10.3969/j.issn.1006-1959.2022.23.029]
[6]陈 嫈.左氧氟沙星致上消化道出血再发2例报道[J].医学信息,2021,34(08):192.[doi:10.3969/j.issn.1006-1959.2021.08.054]
[7]叶芳芳,周志明,曾文宏.哌拉西林钠他唑巴坦钠联合左氧氟沙星对支气管扩张患者气道功能、炎症反应的影响[J].医学信息,2023,36(01):103.[doi:10.3969/j.issn.1006-1959.2023.01.020]
　YE Fang-fang,ZHOU Zhi-ming,ZENG Wen-hong.Effect of Piperacillin Sodium and Tazobactam Sodium Combined with Levofloxacin on Airway Function and Inflammatory Response in Patients with Bronchiectasis[J].Journal of Medical Information,2023,36(18):103.[doi:10.3969/j.issn.1006-1959.2023.01.020]
[8]魏长斌.头孢哌酮钠舒巴坦钠对糖尿病合并尿路感染的疗效及安全性分析[J].医学信息,2021,34(14):151.[doi:10.3969/j.issn.1006-1959.2021.14.042]
　WEI Chang-bin.Analysis of the Efficacy and Safety of Cefoperazone Sodium and Sulbactam Sodium on Diabetes Complicated with Urinary Tract Infection[J].Journal of Medical Information,2021,34(18):151.[doi:10.3969/j.issn.1006-1959.2021.14.042]
[9]谢艳红,冯 莉.左氧氟沙星对老年肺结核患者血清IL-6及IFN-γ水平的影响[J].医学信息,2021,34(16):118.[doi:10.3969/j.issn.1006-1959.2021.16.032]
　XIE Yan-hong,FENG Li.Effect of Levofloxacin on Serum IL-6 and IFN-γ Levels in Elderly Patients with Pulmonary Tuberculosis[J].Journal of Medical Information,2021,34(18):118.[doi:10.3969/j.issn.1006-1959.2021.16.032]
[10]谢艳红.左氧氟沙星联合利福喷丁胶囊治疗老年初治肺结核患者的效果[J].医学信息,2021,34(17):151.[doi:10.3969/j.issn.1006-1959.2021.17.040]
　XIE Yan-hong.The Effect of Levofloxacin Combined with Rifapentine Capsule in the Treatment of Pulmonary Tuberculosis in the Elderly[J].Journal of Medical Information,2021,34(18):151.[doi:10.3969/j.issn.1006-1959.2021.17.040]

更新日期/Last Update: 1900-01-01